ABCL635 Phase 2 blowout in menopausal VMS repositions AbCellera as a proprietary drug company; whether the data supports a Phase 3 filing defines the next chapter

AbCellera is a clinical-stage biopharmaceutical company developing ABCL635, a targeted therapeutic for menopausal vasomotor symptoms, which is not yet approved.

AbCellera built its reputation as an antibody discovery platform, but ABCL635 just delivered Phase 2 data in menopausal vasomotor symptoms that exceeded analyst expectations on both frequency and severity endpoints with no serious adverse events. The thesis now turns on whether ABCL635 advances to a Phase 3 design FDA will accept as registrational, converting platform credibility into proprietary drug value. With roughly $540M cash and a $55M quarterly burn, the company has approximately two and a half years of runway, but the single-arm Phase 1 data for ABCL575 in atopic dermatitis and the nascent TCE programs remain unproven and carry no weight yet.